FI933495A0 - Rekombinantadenovirusvacciner - Google Patents

Rekombinantadenovirusvacciner

Info

Publication number
FI933495A0
FI933495A0 FI933495A FI933495A FI933495A0 FI 933495 A0 FI933495 A0 FI 933495A0 FI 933495 A FI933495 A FI 933495A FI 933495 A FI933495 A FI 933495A FI 933495 A0 FI933495 A0 FI 933495A0
Authority
FI
Finland
Prior art keywords
recombinant adenoviruses
antibodies
cell mediated
mediated immunity
warm blooded
Prior art date
Application number
FI933495A
Other languages
English (en)
Other versions
FI933495A (fi
FI114318B (fi
Inventor
Alan Robert Davis
Paul Porwen Hung
Michael David Lubeck
Robert James Natuk
Pranab Kumar Chanda
Shridhara Chikkatur Sha Murthy
Shaw-Guang Lin Lee
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of FI933495A0 publication Critical patent/FI933495A0/fi
Publication of FI933495A publication Critical patent/FI933495A/fi
Application granted granted Critical
Publication of FI114318B publication Critical patent/FI114318B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI933495A 1992-08-07 1993-08-06 Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi FI114318B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92649192A 1992-08-07 1992-08-07
US92649192 1992-08-07

Publications (3)

Publication Number Publication Date
FI933495A0 true FI933495A0 (fi) 1993-08-06
FI933495A FI933495A (fi) 1994-02-08
FI114318B FI114318B (fi) 2004-09-30

Family

ID=25453282

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933495A FI114318B (fi) 1992-08-07 1993-08-06 Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi

Country Status (18)

Country Link
EP (1) EP0586076B1 (fi)
JP (1) JP4093597B2 (fi)
KR (1) KR100347219B1 (fi)
AT (1) ATE243755T1 (fi)
AU (2) AU680826B2 (fi)
BR (1) BR9303226A (fi)
CA (1) CA2101463C (fi)
DE (1) DE69333057T2 (fi)
DK (1) DK0586076T3 (fi)
ES (1) ES2201055T3 (fi)
FI (1) FI114318B (fi)
HK (1) HK1009978A1 (fi)
HU (2) HU214364B (fi)
IL (1) IL106508A (fi)
MX (1) MX9304765A (fi)
NZ (1) NZ248328A (fi)
PT (1) PT586076E (fi)
ZA (1) ZA935355B (fi)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2196018T3 (es) * 1993-08-11 2003-12-16 Wyeth Corp Vacunas de adenovirus recombinantes.
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide for vaccination against the umbilical cord virus
FR2727867B1 (fr) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
WO1996020732A2 (en) * 1994-12-30 1996-07-11 Chiron Corporation Non-traumatic administration of gene delivery vehicles
KR100464395B1 (ko) * 1997-10-13 2005-02-28 삼성전자주식회사 반도체소자의비아홀형성방법
JP2003530307A (ja) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド gag遺伝子保有アデノウイルスHIVワクチン
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US8926987B2 (en) 2004-11-18 2015-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Replication-competent adenoviral vectors
US9132031B2 (en) 2006-09-26 2015-09-15 Zeltiq Aesthetics, Inc. Cooling device having a plurality of controllable cooling elements to provide a predetermined cooling profile
US20080287839A1 (en) 2007-05-18 2008-11-20 Juniper Medical, Inc. Method of enhanced removal of heat from subcutaneous lipid-rich cells and treatment apparatus having an actuator
US8523927B2 (en) 2007-07-13 2013-09-03 Zeltiq Aesthetics, Inc. System for treating lipid-rich regions
WO2009026471A1 (en) 2007-08-21 2009-02-26 Zeltiq Aesthetics, Inc. Monitoring the cooling of subcutaneous lipid-rich cells, such as the cooling of adipose tissue
US8603073B2 (en) 2008-12-17 2013-12-10 Zeltiq Aesthetics, Inc. Systems and methods with interrupt/resume capabilities for treating subcutaneous lipid-rich cells
US8702774B2 (en) 2009-04-30 2014-04-22 Zeltiq Aesthetics, Inc. Device, system and method of removing heat from subcutaneous lipid-rich cells
BR112012018521A2 (pt) 2010-01-25 2019-09-24 Zeltiq Aesthetics Inc aplicadores para uso doméstico para remover de forma não invasiva calor de células subcutâneas ricas em lipídeos por meio de refrigerantes de mudança de fase, e dispositivos, sistemas e métodos associados
US8676338B2 (en) 2010-07-20 2014-03-18 Zeltiq Aesthetics, Inc. Combined modality treatment systems, methods and apparatus for body contouring applications
WO2012103242A1 (en) 2011-01-25 2012-08-02 Zeltiq Aesthetics, Inc. Devices, application systems and methods with localized heat flux zones for removing heat from subcutaneous lipid-rich cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925784A (en) * 1986-04-04 1990-05-15 Hoffmann-La Roche Inc. Expression and purification of an HTLV-III gag/env gene protein
US5585264A (en) * 1988-07-15 1996-12-17 University Of Saskatchewan Nucleotide sequences encoding recombinant bovine herpesvirus type-1 GI, GIII and GIV polypeptides
GB8919102D0 (en) * 1989-08-22 1989-10-04 Oxford Virology Ltd A recombinant adenovirus dna sequence,a recombinant adenovirus expressing the dna sequence and a rhabdovirus vaccine including the recombinant adenovirus
WO1992011028A1 (en) * 1990-12-19 1992-07-09 Epitope, Inc. Hiv reverse transcriptase vaccine
GB9114437D0 (en) * 1991-07-03 1991-08-21 Health Lab Service Board Recombinant adenoviruses and the use thereof for detecting the presence in eukaryotic cells of the expression products of specific genes

Also Published As

Publication number Publication date
NZ248328A (en) 1997-05-26
AU4446593A (en) 1994-02-10
DE69333057D1 (de) 2003-07-31
ATE243755T1 (de) 2003-07-15
KR100347219B1 (ko) 2003-02-25
HU211691A9 (en) 1995-12-28
HU214364B (hu) 1998-03-30
CA2101463C (en) 2007-03-13
CA2101463A1 (en) 1994-02-08
PT586076E (pt) 2003-11-28
IL106508A (en) 1998-02-22
HK1009978A1 (en) 1999-06-11
ES2201055T3 (es) 2004-03-16
AU715190B2 (en) 2000-01-20
IL106508A0 (en) 1993-11-15
EP0586076B1 (en) 2003-06-25
JP4093597B2 (ja) 2008-06-04
KR940003566A (ko) 1994-03-12
AU3422797A (en) 1997-11-20
BR9303226A (pt) 1994-03-08
MX9304765A (es) 1995-01-31
HU9302285D0 (en) 1993-11-29
EP0586076A3 (en) 1994-04-20
EP0586076A2 (en) 1994-03-09
FI933495A (fi) 1994-02-08
HUT67302A (en) 1995-03-28
FI114318B (fi) 2004-09-30
AU680826B2 (en) 1997-08-14
ZA935355B (en) 1995-01-23
JPH06165689A (ja) 1994-06-14
DK0586076T3 (da) 2003-10-20
DE69333057T2 (de) 2004-07-08

Similar Documents

Publication Publication Date Title
DE69333057D1 (de) Rekombinente Adenoviren-Impfstoffe
AU576907B2 (en) Oral vaccines comprising live recombinant adenoviruses
FI113621B (fi) Menetelmä rekombinanttiadenovirusrokotteiden valmistamiseksi
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
MX9201970A (es) Proteinas superficiales del virus de la hepatitis b con un contenido reducido del carbohidrato huesped.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 114318

Country of ref document: FI